ACRS logo

ACRS Aclaris Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$3.60
-0.32 (-8.04%)

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet…

Market Cap: $571.80Mwww.aclaristx.com

Price

No data yet.

Social Signal Score

52
5d
—
30d
52
4 mentions
—
60d
52
4 mentions
—
90d
52
5 mentions
—
news: 5

Analyst Ratings

17 analysts
Buyconsensus
Strong Buy 0Buy 14Hold 3Sell 0Strong Sell 0
Avg price target$9.5+163.5%
Low $9Median $9.5High $10
Current Consensus

Revenue

$1.48M
$0.00$6.34M$12.68M$19.02M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.53
$-0.56–$-0.51
5 analysts
FY2026
$-0.60
$-0.61–$-0.59
8 analysts
FY2027
$-0.67
$-0.85–$-0.49
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Neal S. Walker
Sector
Healthcare
Industry
Biotechnology
Employees
71
Beta
0.80
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-0.44
www.aclaristx.com